Journal article icon

Journal article

The effect of different etiologies of hepatic impairment on the pharmacokinetics of gefitinib.

Abstract:

PURPOSE: We investigated whether the pharmacokinetics and tolerability of gefitinib were altered in patients with hepatic impairment due to cirrhosis or hepatic metastases in two open, parallel-group, multicenter studies. METHODS: In Study 1, subjects with normal hepatic function or mild, moderate, or severe hepatic impairment (Child-Pugh criteria) due to cirrhosis received single-dose gefitinib 250 mg (n = 10 per group). In Study 2, patients with solid malignant tumors with normal liver bio...

Expand abstract
Publication status:
Published

Actions


Access Document


Publisher copy:
10.1007/s00280-011-1611-2

Authors


Expand authors...
Journal:
Cancer chemotherapy and pharmacology
Volume:
68
Issue:
6
Pages:
1485-1495
Publication date:
2011-12-05
DOI:
EISSN:
1432-0843
ISSN:
0344-5704
URN:
uuid:91694ce6-3b1a-4f2c-92cd-d3200b40af9c
Source identifiers:
316118
Local pid:
pubs:316118

Terms of use


Metrics


Views and Downloads






If you are the owner of this record, you can report an update to it here: Report update to this record

TO TOP